Lifitegrast

(Xiidra®)

Xiidra®

Drug updated on 11/13/2023

Dosage FormSolution (topical; 5%)
Drug Classlymphocyte function-associated antigen-1 (LFA-1) antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of the signs and symptoms of dry eye disease (DED).

Product Monograph / Prescribing Information

Document TitleYearSource
Xiidra (lifitegrast) Prescribing Information.2020Novartis Pharmaceuticals Corporation, East Hanover, NJ

Systematic Reviews / Meta-Analyses